Abstract
We read with great interest the recent retrospective analysis by Fan and colleagues on the outcomes of tofacitinib (TOF) or tacrolimus (TAC) in combination with glucocorticoids for melanoma differentiation-associated gene 5 (MDA5)-related interstitial lung disease (MDA5-ILD), published in The Journal of Rheumatology.1 The authors mainly investigated whether TOF exposure was associated with reduced mortality at 6 months and 1 year, and also compared the incidence of adverse events and discontinuation rates in the TOF and TAC groups for the treatment of MDA5-ILD.